Kjell Stenberg new CEO in Cyxone AB
Cyxone AB (publ), a biotech company in autoimmune diseases, has decided to appoint Kjell Stenberg as new CEO with immediate effect. Kjell replaces Carl-Magnus Högerkorp, who will ensure a smooth transition.Kjell was the CEO of Cyxone from when the company was founded in 2015 until 2019. He has thus good knowledge of Cyxone’s projects, which facilitates a seamless change of management. Kjell holds a PhD in medical science, has held management positions in AstraZeneca R&D including project inlicensing from biotech. Since 2001 he has worked in biotech and with corporate financing in Europe